Next Article in Journal
Flow Cytometric Challenges in Plasmacytoid Dendritic Cell (pDC) Identification: Limitation of BDCA-4 (CD304)-Based Gating
Previous Article in Journal
Cyclodextrin Complexes for Clinical Translatability: Applications for Cladribine and Retrometabolically Designed Estredox
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 26
Issue 22
10.3390/ijms262210977
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Targeting TOMM40 and TOMM22 to Rescue Statin-Impaired Mitochondrial Function, Dynamics, and Mitophagy in Skeletal Myotubes

by
Neil V. Yang
1,2,
Sean Rogers
3,
Rachel Guerra
3,
Justin Y. Chao
1,
David J. Pagliarini
3,4,5,
Elizabeth Theusch
2 and
Ronald M. Krauss
1,2,6,*
1
Department of Nutritional Sciences & Toxicology, University of California, Berkeley, CA 94704, USA
2
Department of Pediatrics, University of California, San Francisco, CA 90048, USA
3
Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110, USA
4
Department of Biochemistry and Molecular BioPhysics, Washington University School of Medicine, St. Louis, MO 63110, USA
5
Department of Genetics, Washington University School of Medicine, St. Louis, MO 63110, USA
6
Department of Medicine, University of California, San Francisco, CA 90048, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2025, 26(22), 10977; https://doi.org/10.3390/ijms262210977
Submission received: 17 October 2025 / Revised: 6 November 2025 / Accepted: 7 November 2025 / Published: 13 November 2025
(This article belongs to the Section Biochemistry)
Browse Figures
Review Reports Versions Notes

Abstract

Statins are the drugs most commonly used for lowering plasma low-density lipoprotein (LDL) cholesterol levels and reducing cardiovascular disease risk. Although generally well-tolerated, statins can induce myopathy, a major cause of non-adherence to treatment. Impaired mitochondrial function has been implicated in the development of statin-induced myopathy, but the underlying mechanism remains unclear. We have shown that simvastatin downregulates the transcription of TOMM40 and TOMM22, genes that encode major subunits of the translocase of the outer mitochondrial membrane (TOM) complex. Mitochondrial effects of knockdown of TOMM40 and TOMM22 in mouse C2C12 and primary human skeletal cell myotubes include impaired oxidative function, increased superoxide production, reduced cholesterol and CoQ levels, and disrupted markers of mitochondrial dynamics and morphology as well as increased mitophagy, with similar effects resulting from simvastatin exposure. Overexpression of TOMM40 and TOMM22 in simvastatin-treated mouse and human skeletal muscle cells rescued effects on markers of mitochondrial dynamics and morphology, but not oxidative function or cholesterol and CoQ levels. These results show that TOMM40 and TOMM22 have key roles in maintaining both mitochondrial dynamics and function and indicate that their downregulation by statin treatment results in mitochondrial effects that may contribute to statin-induced myopathy.

1. Introduction

Statins, the most widely used class of drugs for reducing plasma LDL-cholesterol levels and cardiovascular disease risk, act by inhibiting 3-hydroxy-3-methyglutaryl coenzyme A reductase (HMGCR), the rate-limiting enzyme for cholesterol synthesis [1,2]. Although statins are highly effective and generally well-tolerated, they can have adverse side effects, the most common being statin-associated muscle symptoms (SAMS) [3,4] ranging from myalgia and myositis to rhabdomyolysis [5]. Among the currently used statins, simvastatin has been associated with the greatest incidence of SAMS [6].
Disruption of mitochondrial function has been proposed as a major mechanism contributing to SAMS [7]. Effects of statins on skeletal muscle mitochondria phenotypes have been demonstrated in cellular, animal, and clinical studies [8,9]. These include increased reactive oxygen species (ROS) [10], decreased mitochondrial biogenesis [11], altered protein prenylation, decreased intracellular ATP levels [12,13], altered electron transport chain protein expression, increased fragmentation of mtDNA [14], and elevated plasma creatine kinase (CK) levels [15]. Additionally, statin-induced inhibition of the synthesis of coenzyme Q (CoQ10), an essential cofactor of the electron transport chain, has been proposed as a major contributing factor to skeletal muscle mitochondrial dysfunction [16]. Despite these findings, little is known of the molecular basis for these statin effects.
Recently, Grunwald et al. reported that simvastatin exposure of myotubes derived from primary human myoblasts resulted in a significant 50% reduction in expression of TOMM40 and TOMM22 [17], two broadly expressed and highly conserved genes encoding components of the translocase of the outer mitochondrial membrane (TOM) complex [18]. We have observed a similar effect of simvastatin in a panel of human lymphoblastoid cell lines [19]. TOMM40 and TOMM22 were among the top 22 transcripts downregulated by simvastatin treatment. The mammalian TOM complex consists of seven subunits that work together to recognize and import proteins from the cytoplasm into the mitochondrial interior to maintain mitochondrial function [20,21] (Figure 1A). Among these subunits, TOMM40 is the main channel-forming subunit that is stably associated with TOMM22, the central receptor of the complex [22]. Together, they are actively involved in protein translocation across the mitochondrial outer membrane [23]. We have previously shown in hepatocytes that TOMM40 plays a central role at mitochondria-ER contact sites (MERCs) in regulating hepatocellular cholesterol and lipid metabolism [24]. In addition, TOMM40 is known to interact with several ER membrane proteins at mitochondria-ER contact sites (MERCs) including B cell receptor-associated protein 31 (BCAP31), which has been shown to regulate cell death and crosstalk signaling between ER and mitochondria [25,26], while TOMM22 binds with PINK1 to eliminate damaged mitochondria via mitophagy [27].
In the present study, we performed detailed mitochondrial phenotyping to compare the effects of TOMM40 and TOMM22 knockdown with the effects of simvastatin treatment in two mammalian skeletal muscle cell models—mouse C2C12 cells, which are known to display cellular phenotypes with statin treatment similar to those seen with statin-induced myotoxicity in humans [28], and primary human skeletal muscle cells (hSkMCs). We also tested the role of TOMM40 and TOMM22 downregulation in mediating statin’s mitochondrial effects by determining whether these effects were rescued by overexpressing these genes. Finally, we showed that the transcription of BCAP31 was reduced by both statin treatment and TOMM40 knockdown, and therefore tested whether reduced TOMM40 expression may play a role in mediating the mitochondrial effects of statin in skeletal muscle cells.

2. Results

2.1. Simvastatin Downregulates Key Subunits of the TOM Complex in Mammalian Skeletal Muscle Cells

We first aimed to confirm previous findings in primary human myotubes [23] that the expression of TOMM40 and TOMM22 was downregulated by simvastatin exposure. Differentiated C2C12 and primary hSkMC myotubes were treated with 2 µM simvastatin for 24 h. This dose was chosen based on simvastatin dose response experiments that showed significant induction of Hmgcr and Ldlr mRNA at 2 µM in C2C12 cells (Figure S1). Additionally, we performed a simvastatin dose-response experiment in C2C12 cells to assess apoptosis using EarlyTox Caspase-3/7 and found no significant increase with simvastatin 2 µM vs. the baseline (Figure S2). In both cell types, mRNA transcript levels of TOMM40 and TOMM22 were significantly reduced by exposure to 2 µM simvastatin as assessed by qRT-PCR (Figure 1B,C). We also confirmed significant reductions in TOMM40 and TOMM22 protein levels in primary hSkMC myotubes exposed to 2 µM simvastatin by Western blot (Figure S3). Transcript levels of two other subunits of the TOM complex, Tomm20 and Tomm5, were also significantly reduced by simvastatin in the C2C12 myotubes but not primary hSkMC myotubes (Figure 1B,C). These results confirm and extend the evidence that simvastatin downregulates the expression of major subunits of the TOM complex.

2.2. TOMM40 and TOMM22 Knockdown Impairs Mitochondrial Function in Skeletal Myotubes

We next sought to assess the potential role of TOMM40 and TOMM22 downregulation by statins in mediating mitochondrial dysfunction by studying the effects of TOMM40 and TOMM22 knockdown (KD) in C2C12 and hSkMC myotubes. KD of Tomm40 and Tomm22 singly and in combination was performed by a two-step siRNA transfection (Figure 2A), resulting in greater than ~80% knockdown efficiency (Figure 2B). In addition, we compared the KD efficiency in differentiated myotubes vs. undifferentiated myoblasts in C2C12 and hSkMCs and found no differences in TOMM40 and TOMM22 mRNA transcript levels (Figure S4). In both the C2C12 and hSkMC myotubes, the basal and maximal oxygen consumption rate (OCR) as well as ATP production were significantly reduced by each condition compared with a non-targeting control (NTC), indicating impaired electron transport chain and mitochondrial function (Figure 2C–F).
To confirm a decrease in mitochondrial respiration due to the suppression of TOMM40 and TOMM22 gene expression, we measured mitochondrial superoxide (mitochondrial reactive oxygen species, a.k.a. mitoROS) production using a fluorescence indicator (MitoSOX™) in C2C12 myotubes. This showed increased mitochondrial superoxide production in C2C12 cells transfected with both Tomm40 and Tomm22 siRNAs compared with NTC (Figure 2G). Though there was an increased trend observed in cells transfected with Tomm40 siRNA individually (p = 0.171), no significant differences were observed in Tomm22 KD cells alone. These results demonstrate that KD of either TOMM40 or TOMM22 in skeletal myotubes impairs mitochondrial respiration and that their combined KD promotes the generation of mitoROS.

2.3. Tomm40 and Tomm22 KD Reduces Cholesterol and CoQ Levels in Mitochondria of C2C12 Myotubes In Vitro

Since mitochondria require cholesterol for the maintenance of membrane integrity and proper respiratory function [29], and in light of our recent findings that the KD of Tomm40 and Tomm22 reduces the intrahepatic cholesterol content [30], we tested whether suppression of the expression of these genes reduced the mitochondrial cholesterol content in C2C12 myotubes, and whether such an effect contributed to impaired mitochondrial respiration. The isolation of crude mitochondria from C2C12 myotubes was confirmed by the protein expression of Tomm20 and Vdac1 mitochondrial markers on Western blot (Figure S5). Consistent with our hypothesis, a reduction in mitochondrial cholesterol content was observed in both Tomm40 and Tomm22 siRNA-transfected cells, singly and in combination, compared with NTC (Figure 3B). To assess whether reduced cholesterol alone was responsible for the disruption of mitochondrial function by Tomm40 and Tomm22 KD, we performed a cholesterol addback experiment. The addition of LDL isolated from human plasma rescued the mitochondrial cholesterol content of the Tomm22 KD but not Tomm40 KD myotubes (Figure 3C,D). However, cholesterol repletion in the Tomm22 KD myotubes did not restore reduced mitochondrial ATP production and basal respiration (Figure 3E,F).
Given that CoQ, which shares intermediate biosynthetic steps with cholesterol, plays a central role in the mitochondrial electron transport chain, we next tested the effects of Tomm40 and Tomm22 KD on the mitochondrial CoQ levels. Since mice, unlike humans, predominantly synthesize CoQ9 (9 prenyl units), we analyzed the CoQ9 levels in our murine C2C12 cell model [31]. While Tomm40 and Tomm22 KD, singly and in combination, resulted in no differences in the levels of CoQ (Figure S6) in whole cell lysates, there were significant reductions in CoQ9 in isolated mitochondria (Figure 3G). Together, these results indicate that TOMM40 and TOMM22 of the TOM complex may impact mitochondrial function in skeletal myotubes at least in part via its effect on the CoQ biosynthesis pathway.

2.4. TOMM40 and TOMM22 KD Upregulate Markers of Mitochondrial Fission and Mitophagy in Response to Mitochondrial Damage

Having observed mitochondrial dysfunction with the suppression of TOMM40 and TOMM22, we next investigated markers of mitochondrial dynamics, a key process that regulates cellular and mitochondrial metabolism [32]. Through the transmission electron microscopy (TEM) of C2C12 myotubes transfected with Tomm22 and Tomm40 siRNAs compared with NTC, we observed an increase in constriction events within individual mitochondria, indicative of increased fission events (Figure 4A), along with a significant decrease in average mitochondrial length (Figure 4B), but not width (Figure 4C). This change in mitochondrial morphology led us to hypothesize that Tomm40 and Tomm22 KD affects the mitochondrial dynamics in skeletal muscle. Through qPCR in TOMM22 and TOMM40 KD C2C12 and hSkMCs, we observed upregulated expression of FIS1 and DNM1L/DRP1, genes that encode markers of mitochondrial fission (Figure 4D,E). This was accompanied by a decrease in the gene expression of the mitochondrial fusion markers MFN2 and OPA1. With a shift toward mitochondrial fission in TOMM22 and TOMM40 KD skeletal muscle cells, we observed an increase in mitochondrial density (Figure 4F) and mtDNA copy number (Figure 4G), which together suggest increased mitochondrial damage and support the excessive mitochondrial fragmentation observed.
We further used TEM for analyzing the mitochondrial morphology to assess mitochondrial damage (Figure 5A). KD of Tomm40 and Tomm22 resulted in a reduced percentage of type 1 (healthy) mitochondria and an increase in both types 2 and 3 (damaged and ruptured) mitochondria (Figure 5B,C) [33]. Collectively, these results indicate that while there was an increase in new mitochondria created from fission events in knockdown cells (as confirmed in Figure 4F,G), the majority were damaged. Furthermore, we noticed a significant increase in the percentage of mitophagosomes in the Tomm40 and Tomm22 KD C2C12 cells (Figure 5D). This observation was confirmed by an increase in the gene and protein expression of the mitophagy markers PINK1 and PRKN in hSkMCs (Figure 5E,F). Accordingly, these results support a compensatory mechanism due to the mitochondrial damage induced by TOMM40 and TOMM22 KD in which markers of mitochondrial fission are upregulated, leading to increased mitophagy that removes damaged mitochondria and maintains mitochondrial homeostasis.
In vivo, gastrocnemius skeletal muscle isolated from AAV8-Tomm40 shRNA injected male mice (14-weeks old) showed a significant reduction in mitochondria number (Figure 5I). In addition, mitochondria morphology was affected so that the lengths of the intermyofibrillar and subsarcolemmal mitochondria were both reduced (Figure 5J,K). Consistent with our in vitro findings, the percent of ruptured mitochondria increased drastically in the Tomm40 shRNA-induced male mice, indicating signs of mitochondrial damage and dysfunction (Figure 5L) [34]. Gastrocnemius skeletal muscles from AAV8-Tomm40 shRNA female mice were not affected and presented no indications of mitochondrial damage (Figure S8).

2.5. Overexpression of TOMM40 and BCAP31 Rescues Statin-Induced Mitochondrial Dysfunction

We next sought to determine whether overexpressing TOMM40 and TOMM22, singly and in combination, could rescue simvastatin-induced effects on mitochondrial function. First, we demonstrated that treatment of C2C12 and hSkMCs with 2 µM simvastatin for 24 h resulted in decreased OCR (both basal and maximal oxygen consumption) and ATP production (Figure 6A,B). Accordingly, mitoROS production was increased by simvastatin in skeletal myotubes (Figure 6E). Introduction of TOMM40- and TOMM22-containing lentiviral plasmids, singly and in combination, to these simvastatin-treated cells resulted in no changes in the OCR and mitoROS levels (Figure 6A,B). Similarly, over-expressing Tomm20, another key component of the TOM complex, did not reverse the simvastatin effect on basal respiration, ATP production, and mitoROS levels in C2C12 cells (Figure 6A–C).
Since TOMM40 is known to impact mitochondrial function by binding to BCAP31 at MERCs [25] and having shown that 2uM simvastatin decreases BCAP31 expression (Figure 6D,E), we then tested whether TOMM40 and/or TOMM22 required BCAP31 to rescue simvastatin-induced mitochondria dysfunction. We found that overexpressing both TOMM40 and BCAP31 in simvastatin-treated C2C12 and hSkMC myotubes resulted in the rescue of ATP production, basal respiration, maximal respiration, and proton leak (Figure 6F–M). However, TOMM22 in combination with BCAP31 did not rescue mitochondria function in simvastatin treated cells, consistent with previous evidence of a TOMM40–BCAP31 specific interaction [25].
In accord with the inhibition of mevalonate synthesis by statins1, simvastatin (2 µM for 24 h) resulted in reduced levels of two products of the mevalonate/CoQ biosynthesis pathway—cholesterol and CoQ—in mitochondria isolated from C2C12 cells by subcellular fractionation (Figure 6N,O). These effects were not reversed by the overexpression of Tomm40 and Tomm22, or of Tomm20. Nor did the overexpression of Bcap31 with Tomm40 or Tomm22 increase the mitochondrial cholesterol levels to the baseline levels (Figure S9). Together, these results indicate that there are other effects of statin besides the downregulation of Tomm40, Tomm22, Tomm20, and Bcap31, which are primarily responsible for modulating the cholesterol (Figure S9) and CoQ (Figure 3G) content in the mitochondria of skeletal muscle cells.

2.6. TOMM40 and TOMM22 Rescue Statin-Disrupted Regulators of Mitochondrial Fusion and Fission Events

As observed with Tomm40 and Tomm22 KD, TEM image analysis of C2C12 myotubes treated with simvastatin 2 µM for 24 h (Figure 7A) resulted in reduced mitochondria length and increased width (Figure 7B,C). The likelihood that this resulted from increased mitochondrial fission events is supported by a qPCR analysis showing that simvastatin treatment resulted in the increased expression of FIS1 and DRP1 and reduced expression of MFN2 and OPA1 (Figure 7D,E). Furthermore, both mitochondrial density and mtDNA copy number increased in simvastatin-treated C2C12 myotubes compared with the control (Figure 7F,G). Thus, as with TOMM40 and TOMM22 KD, simvastatin treatment of skeletal myotubes upregulated markers of mitochondrial fission and damage.
We next tested whether overexpressing TOMM40 and TOMM22, singly and in combination, could rescue these effects of simvastatin on mitochondrial dynamics. Notably, there was a reversal of statin effects on mitochondrial length and width after the addition of Tomm40 and Tomm22/40 plasmids in C2C12 myotubes (Figure 7B,C). Moreover, TOMM40 and TOMM22 overexpression in both C2C12 and hSkMCs resulted in reversal of the statin effects on the gene expression of the mitochondrial fission and fusion markers described above (Figure 7D,E). These gene expression results were confirmed at the protein level, where simvastatin-induced changes in the protein expression of OPA1 and MFN2 fusion markers, and DRP1 fission markers were restored after overexpressing TOMM40 or TOMM22 in hSkMCs (Figure S10). Although BCAP31 in conjunction with TOMM40 or TOMM22 overexpression rescued the gene expression of mitochondrial fission and fusion markers, BCAP31 alone only rescued FIS1 gene expression (Figure S11). This suggests that other than BCAP31’s known interaction with FIS1, it is not required for rescuing simvastatin-induced mitochondria dynamics.
Interestingly, the addback of Tomm40 and Tomm22 plasmids to the simvastatin-treated cells resulted in further increases in mtDNA copy number and mitochondrial density (Figure 7F,G). Together with the evidence that TOMM40 and TOMM22 expression reverses statin effects on regulators of mitochondrial dynamics, this suggests that this treatment may suppress statin-induced mitophagy while generating new, healthy mitochondria. Consistent with this hypothesis, we observed by TEM that the simvastatin-treated C2C12 cells had a lower percentage of healthy type 1 mitochondria (sharp cristae and dense matrix) and a higher percentage of type 2 (dilute cristae and/or dilute matrix) and type 3 (ruptured) mitochondria, representing abnormal mitochondrial morphology and signs of mitochondrial injury [7]. In addition, there was an increase in the percentage of mitophagosomes per cell in the simvastatin-treated skeletal muscle (Figure 8D). Consistent with these observations, we demonstrated an increased expression of mitophagy biomarkers PINK1 and PARKIN with simvastatin treatment by qPCR (Figure 8E,F).
We then showed through TEM that overexpressing Tomm40 and Tomm22 in statin-treated C2C12 myotubes resulted in an increase in type 1 mitochondria and a reduction in type 2 and type 3 mitochondria, indicating that Tomm22 and Tomm40 are able to rescue, at least in part, simvastatin-induced mitophagy. Consistent with this effect, TOMM22, TOMM40, and TOMM22/40 (but not Tomm20) overexpression reduced PINK1 and PARKIN expression to the control levels (Figure 8E,F). In summary, these results demonstrate that simvastatin promotes regulators of mitochondrial fission and mitophagy, resulting in an increase in damaged mitochondria, while overexpressing TOMM22 and TOMM40 can reverse these effects, thus maintaining mitochondrial quality and homeostasis.

3. Discussion

Statin-associated myopathy is the most prevalent adverse effect among statin users, but its mechanism remains unclear [35]. We here report that TOMM40 and TOMM22, key members of the TOM complex whose transcriptional expression is suppressed by simvastatin in skeletal muscle cells, are essential in maintaining mitochondrial function and quality by promoting their oxidative function, retaining CoQ and cholesterol content, and preserving their morphology and dynamics. Consistent with our findings in skeletal muscle, previous studies in epithelial ovarian cancer and HeLa cell lines showed that knockdown of TOMM40 disrupted mitochondrial membrane potential, ATP, and ROS levels [36,37,38,39]. It has been suggested that mitochondrial dysfunction due to the suppression of TOMM40 and TOMM22 is caused by interference with the uptake of mitochondria-targeted proteins [40]. Notably, in the case of TOMM22, its suppression or mutation results in the inactivation of mitochondrial proteins due to misfolding in yeast [41] as well as apoptosis of human epithelial and endothelial cells and zebrafish hepatocytes [42].
We also found that TOMM40 and TOMM22 KD reduced the cholesterol content in skeletal muscle cells and isolated mitochondria, suggesting that this effect contributes to the mitochondrial dysfunction observed with the KD of these TOM components. Interestingly, adding back LDL cholesterol restored the mitochondrial cholesterol levels in TOMM22 KD skeletal myotubes, but not in the TOMM40 KD cells, suggesting that TOMM40 is necessary for maintaining cholesterol levels in muscle mitochondria [43]. However, neither KD group showed an improvement in mitochondrial OCR after the addition of LDL, indicating that under these conditions, mitochondrial respiration and function are regulated by factors other than cholesterol content, or possibly that the added cholesterol was not effectively introduced into the mitochondrial membrane.
CoQ10 (humans) or CoQ9 (in mice) in the CoQ biosynthesis pathway, essential for regulating the mitochondria electron transport chain and thus mitochondrial function, are dependent on isoprenoids, products of the mevalonate pathway [44]. To date, it is still unclear how CoQ and its precursors are transported across the outer mitochondrial membrane into the mitochondrial matrix of skeletal muscle cells. However, recently, Tai et al. [45] showed in Saccharomyces cerevisiae that isopentenyl pyrophosphate (IPP) molecules, precursors of both CoQ and cholesterol, may enter the mitochondrial matrix via an IPP transporter situated on the inner mitochondrial membrane. Together with our results showing that TOMM40 and TOMM22 KD in C2C12 skeletal myotubes resulted in a significant reduction in mitochondrial CoQ content, we suggest that TOMM40 and TOMM22 may affect the transport of proteins required for CoQ biosynthesis, including those involved in the transport of 4-hydroxybenzoate (4-HB) and isoprenoid pyrophosphates, into the mitochondria [46]. Further studies are necessary to determine which transporters and enzymes of the CoQ biosynthesis pathway are recognized and imported into mitochondria by TOMM40 and TOMM22, thus promoting CoQ synthesis [47]. Despite differences in mitochondrial CoQ, the CoQ levels in the whole cell lysates were unaffected, suggesting that decreased mitochondrial CoQ production may be compensated by the promotion of CoQ synthesis in the Golgi apparatus [31,48], a possibility that requires further investigation. Future studies should also investigate the role of CoQ10 in hSkMCs to confirm the relevance of these findings in humans.
Mitochondrial dynamics involves the coordination of fusion and fission events that define mitochondria number, size, and morphology [49]. Accumulating evidence has revealed a strong association between mitochondrial function and dynamics [50,51]. In addition, genes regulating mitochondrial dynamics, including MSTO1, have been shown to impact other cellular functions including oxidative stress, apoptosis, and mitophagy as well as to induce myopathy and ataxia [52,53,54]. We show here for the first time, using both TEM and expression of mitochondrial dynamic biomarkers, that the KD of TOMM40 and TOMM22 in skeletal myotubes causes a shift toward increased mitochondrial fission, with a resulting increase in mitophagy as a means of eliminating damaged mitochondria and maintaining mitochondria quality [55,56]. It is plausible that TOMM40 regulates mitochondrial fusion and fission by directly or indirectly interacting with known markers of fission and fusion localized at MERCs such as FIS1, DRP1, and MFN2 [57]. Further studies using fluorescence resonance energy transfer (FRET) with live-cell imaging will be required to assess the interaction and localization of mitochondrial dynamic probes [58].
Additionally, studies in yeast have shown TOMM22 to interact with PINK1, a key regulator of mitochondrial quality and mitophagy [59,60,61,62,63,64]. In mammalian cells, dephosphorylation of TOMM22 impairs PINK1 import into the mitochondria, promoting mitophagy [65]. The effect on mitophagy may be mediated, at least in part, by increased mitoROS as a consequence of mitochondrial dysfunction [66,67]. Consistent with this mechanism, we observed that both mitoROS levels and the mitophagy markers PINK1 and PRKN were upregulated with TOMM40 and TOMM22 KD. Thus, our results indicate TOMM40 and TOMM22 to be key genes in regulating mitochondrial function, dynamics, and mitophagy.
Based on these findings and the evidence that simvastatin downregulates TOMM40 and TOMM22 gene expression, we compared the effects of simvastatin exposure with those of TOMM40 and TOMM22 knockdown on mitochondrial function and dynamics and tested whether the overexpression of these genes could reverse the statin effects. We showed that simvastatin treatment exerted effects on biomarkers of mitochondrial dynamics and morphology in skeletal muscle cells similar to those observed with both TOMM40 and TOMM22 KD. Previous studies in yeast cells reported that statins impair mitochondrial morphology, represented by an increase in aggregated mitochondria, due to disruption of mitochondrial function and membrane potential [68,69,70]. However, we are the first to show that the reduction in mitochondrial length and increased mitochondrial fragmentation in C2C12 cells exposed to simvastatin can be explained by an increase in mitochondrial fission and decrease in fusion events. As with TOMM40 and TOMM22 KD, the shift toward mitochondrial fission resulted in increased mitophagy (e.g., via PINK1 and PRKN) to promote the removal of damaged mitochondria [71,72]. We also showed in our in vivo model that the KD of TOMM40 in mice presented signs of mitochondrial damage in gastrocnemius skeletal muscle, similar to phenotypes observed with statin treatment in previous rodent studies [34,73]. However, these differences were sex-specific, as the Tomm40 KD had no effect on gastrocnemius skeletal muscle in female mice. This finding is supported by previous in vivo studies that observed female mice showing greater resistance to mitochondrial damage and oxidative stress than males, largely due to the role of estrogen in promoting mitochondrial function and suppressing mitochondrial oxidative stress [74,75]. In addition, since this study used a transient Tomm40 KD mouse model, future studies employing a stable KD or knockout mouse model, and/or a tissue-specific knockout, will be required to more fully assess the role of Tomm40 in both sexes. Notably, the overexpression of TOMM40 and TOMM22 rescued the changes in regulators of mitochondrial dynamics and morphology and mitophagy caused by simvastatin treatment of C2C12 myotubes.
Consistent with previous studies [7,9,10], we showed that simvastatin treatment of C2C12 myotubes resulted in a reduction in ATP production and mitochondrial respiration, together with an increase in mitoROS production. We also observed that simvastatin reduced the free cholesterol content in whole cells as well as in isolated mitochondria [76], an effect that might be linked to impaired mitochondrial structure and membrane potential, rather than mitochondrial function. However, we found that while overexpressing TOMM40 and TOMM22 in simvastatin-treated skeletal myotubes rescued mitochondrial structure and morphology, there was no rescue of the intracellular or mitochondrial cholesterol levels, suggesting that reduced cholesterol content is not responsible for the effects of KD on mitochondrial morphology. Moreover, as also expected from statin inhibition of the mevalonate pathway, we showed that simvastatin treated C2C12 cells exhibited a reduction in mitochondrial CoQ levels, an effect that has been suggested to contribute to SAMS [77]. These results paralleled those observed with TOMM40 and TOMM22 KD, raising the question as to whether the reduced expression of these genes contributes to these statin effects in muscle, as was the case for the statin-induced changes in mitochondrial morphology and biomarkers of dynamics. In the case of CoQ, the effects of simvastatin and TOMM40 and TOMM22 KD were additive (Figure S7). However, overexpression of these genes, including TOMM20, another major TOM complex subunit encoding gene [78] as well as BCAP31, failed to restore statin impairment of mitochondrial CoQ and cholesterol content. Thus, the reduction in mitochondrial cholesterol and CoQ levels by statin may be due primarily to inhibition of the mevalonate pathway and independent of the reduced expression of genes encoding components of the TOM complex.
TOMM40 has been shown to bind to several ER membrane proteins at MERCs [26]. Among these, BCAP31 has been shown to play a key role in maintaining oxidative phosphorylation, where knockdown of BCAP31 in U2OS cells showed impaired mitochondrial function and reduced ATP levels [25]. In addition, we have shown that the knockdown of TOMM40 in skeletal muscle cells downregulates BCAP31 expression (Figure S12). Namba further showed using coimmunoprecipitation that BCAP31 directly binds to TOMM40 and NDUFS4, thereby inducing translocation into the mitochondria of NADH:ubiquinone oxidoreductase (mitochondrial complex I) core subunit 4 (NDUFS4). In addition to TOMM40, BCAP31 is also known to physically interact with FIS1 at MERCs to regulate mitochondrial fusion/fission dynamics and mitochondrial signaling [79,80], Our finding that overexpressing BCAP31 in simvastatin-treated skeletal myotubes rescues FIS1 expression is consistent with the possibility that TOMM40 can regulate mitochondria fission through its direct binding to BCAP31, although further studies will be required to confirm whether overexpressing BCAP31 rescues mitochondrial dynamics and mitophagy in simvastatin-treated skeletal myotubes. We have, however, shown here for the first time that statin exposure of muscle cells reduces BCAP31 gene expression, and that combined overexpression of TOMM40 and BCAP31 in statin-treated C2C12 and hSKMC myotubes is sufficient to rescue impaired mitochondrial oxidative function. This result suggests that statin impairment of mitochondrial respiration can be attributed to disruption of a TOMM40–BCAP31 interaction at MERCs, a mechanism that differs from that responsible for a role of TOMM40 and TOMM20 suppression in mediating statin effects on mitochondrial dynamics and structure. Future studies will be required to determine the direct and indirect interactions of TOMM40, TOMM22, and BCAP31 with other proteins at MERCs that may impact adverse mitochondrial effects of statin treatment and predispose to the development of SAMS.

4. Materials and Methods

4.1. Cell Culture

C2C12 murine myoblasts and primary hSkMCs were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA; CRL-1772 and PCS-950-010). C2C12 cells were cultured in DMEM containing 4.5 g/L glucose and L-glutamine (Gibco, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific, Waltham, MA, USA) and penicillin-streptomycin (Gibco) at 37 °C and 5% CO2. After passaging cells, C2C12 myoblasts were differentiated into myotubes by replacing media with DMEM containing 2% horse serum (Gibco). Fresh medium was replaced every 2 days and cells were incubated for 5–7 days to completely differentiate into myotubes before experimentation. For hSkMCs, cells were cultured in mesenchymal stem cell basal medium (PCS-500-030, ATCC, Manassas, VA, USA) supplemented with L-glutamine, 5 ng/mL rh EGF, 10 µM dexamethasone, 5 ng/mL rh FGF-b, 25 µg/mL rh insulin, 4% FBS (PCS-950-040, ATCC, Manassas, VA, USA), and penicillin-streptomycin (Gibco). At 24–96 h after passaging, hSkMCs were differentiated into myotubes using a skeletal muscle differentiation tool (PCS-950-050, ATCC, Manassas, VA, USA) for 2 days before experimentation. Cells were routinely tested for mycoplasma using a MycoAlert™ PLUS Mycoplasma Detection Kit (Lonza, Basel, Switzerland) and only mycoplasma negative cells were used.

4.2. siRNA Reverse Transfections

To achieve the knockdown (KD) of TOMM22 and TOMM40, C2C12 and hSkMC skeletal myoblast cells were seeded at 100,000 cells per well in 6-well plates. Upon seeding, cells were reverse transfected with 10 µM of non-targeting control (NTC), TOMM22 and/or TOMM40-targeted siRNAs using Lipofectamine RNAiMax transfection reagent (Thermo Fisher Scientific, Waltham, MA, USA), and Opti-MEM 1 (Gibco, Waltham, MA, USA) for 48 h. All siRNAs were purchased from Thermo Fisher Scientific (Waltham, MA, USA)—human TOMM22 siRNA (s32549); human TOMM40 siRNA (s20449); mouse Tomm22 siRNA (s104588); mouse Tomm40 siRNA (s79125); Silencer Select Negative Control siRNA (s79125). For C2C12 and hSkMC, cells were transfected twice, at day 0 (myoblasts) and days 2 (hSKMC) or 3 (C2C12; myotubes) in differentiation media and then harvested after day 5 for experimentation.

4.3. Overexpression Plasmids

Human and mouse pCMV-EGFP expressing-TOMM40/Tomm40 (human: NM_001128916.2, mouse: NM_016871.2), TOMM22/Tomm22 (human: NM_020243.5, mouse: NM_172609.3), Tomm20 (mouse: NM_024214.2), BCAP31/Bcap31 (human: NM_001139457.2, mouse: NM_012060.5), and empty vector (EV; ORF_stuffer) plasmids stored in bacterial glycerol stocks were purchased from VectorBuilder Inc. (Chicago, IL, USA). Expression plasmids were cultured on Luria-Bertani (LB) Agar plates containing ampicillin at 37 °C. Single colonies were selected and grown separately in LB broth at 37 °C with continuous shaking (225 rpm) overnight. DNA plasmids were then purified and extracted using the ZymoPURE II Plasmid Midiprep Kit (Zymogen, Irvine, CA, USA) according to the manufacturer’s protocol. For overexpression studies, both C2C12 and hSkMCs were first differentiated into myotubes using the respective differentiation media. After differentiation, cells were transiently transfected with purified TOMM40/Tomm40, TOMM22/Tomm22, and Tomm20 expression plasmids, singly and in combination, or matched empty vector, using the Lipofectamine 3000 transfection reagent (Thermo Fisher Scientific, Waltham, MA, USA). In parallel, 2 µM simvastatin was added to the cell media, and cells were collected after 24–48 h. Simvastatin was obtained as a gift from Merck Inc. (Whitehouse Station, NJ, USA) and activated to the β-hydroyxyacid form prior to use as previously described [81].

4.4. Animal Studies

The 6-week old C57BL/6J male and female mice (n = 6 per group) were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and placed on a high-fat Western diet. At 8 weeks of age, mice were intraperitoneally (IP) injected with either 4 × 1011 GC AAV8-Tomm40 shRNA or AAV8-CMV-null as a control (VectorBuilder, Chicago, USA). Weekly bodyweight and food intake measurements were recorded. At 14-weeks old, mice were terminated and gastrocnemius muscle tissues were collected and immediately fixed in 2% glutaraldehyde +2% paraformaldehyde solution for transmission electron microscopy.

4.5. Mitochondrial Respiration Measurements

In vitro oxygen consumption rate was measured in fully differentiated C2C12 and hSkMC skeletal myotubes with an Agilent Seahorse XFe96 Extracellular Flux Analyzer (Santa Clara, CA, USA). Skeletal myoblast cells were seeded at 1000 per well in 96-well plates and were incubated for 5–7 days until the myoblasts were fully differentiated into myotubes with a cell density of ~30,000–40,000 cells per well (3–4 × 105 cells/mL), measured with the Countess 3™ automated cell counter (Invitrogen, Carlsbad, CA, USA). Prior to the start of the experiment, skeletal myotubes were incubated in XF assay medium (Agilent, Santa Clara, CA, USA) supplemented with 2 mM sodium pyruvate (Gibco, Waltham, MA, USA), 2 mM GlutaMAX™ (Gibco, Waltham, MA, USA), and 10 mM glucose (Sigma, St. Louis, MO, USA) at pH 7.4. During experimentation, 1.5 µM oligomycin, 2 µM FCCP, and 2 µM Antimycin A + Rotenone (Seahorse XF Cell Mito Stress Test Kit, Agilent, Santa Clara, CA, USA) was added sequentially via injection ports to calculate the basal and maximum respiration and ATP production. Oxygen consumption rate (OCR) values were presented with non-mitochondrial oxygen consumption deducted and normalized to total protein concentration per well using the Bradford assay.

4.6. Fluorescence Quantification

To detect mitochondria superoxide production in C2C12 cells, myotubes were incubated with 5 µM MitoSOX™ Red (Molecular Probes, Eugene, OR, USA) for 20 min at 37 °C. Cells were then rinsed twice in pre-warmed 1× phosphate-buffered saline (PBS), which was then replaced with phenol red-free DMEM (21063029; Gibco, Waltham, MA, USA) supplemented with glucose and sodium pyruvate. Fluorescence was detected and quantified at an excitation/emission of 510/595 nm (with an Ex/Em bandwidth of 10 nm) using an Agilent BioTek™ microplate fluorescence spectroscopy reader (Santa Clara, USA) and BD LSRFortessa™ Cell Analyzer flow cytometer (Franklin Lakes, USA) following the protocol of Kauffman et al. [82]. To minimize the effects of uneven cell distribution, we employed orbital averaging during the readings. To quantify mitochondrial density, MitoTracker™ Deep Red FM (100 nM) was added to the C2C12 cells for 30 min at 37 °C, washed twice with 1× PBS, and replaced with phenol red-free DMEM supplemented with glucose and sodium pyruvate (Gibco, Waltham, MA, USA). MitoTracker fluorescence was quantified at an excitation/emission of 644/665 nm. All absorbance readings were normalized to total protein concentration by the Bradford assay.

4.7. Isolation of Mitochondria by Subcellular Fractionation

Mitochondria were isolated from C2C12 and hSkMCs according to the method of Wettmarshausen and Perocchi [83]. Cells were rinsed in 1× PBS twice, dislodged with 0.25% Trypsin-EDTA (Gibco), washed again in 1× PBS, and centrifuged at 600× g for 5 min at 4 °C. Pelleted cells were resuspended in MSHE + BSA buffer (210 mM mannitol, 70 mM sucrose, 5 mM HEPES, 1 mM EGTA, and 0.5% BSA, at 7.2 pH). Samples were transferred to a small glass dounce and homogenized. The homogenate was centrifuged at 600× g for 10 min at 4 °C, and the supernatant was extracted and centrifuged at 8000× g for 10 min at 4 °C. The isolated pellet containing the purified crude mitochondria was dried down by nitrogen gas and snap frozen in liquid nitrogen for quantification of the mitochondrial cholesterol and CoQ levels.

4.8. Lipid Extraction for LC-MS/MS

C2C12 whole cell lysates and isolated mitochondria pellets were resuspended in 100 µL of 150 mM KCl. Ten percent of the cell suspension was removed from each tube and placed into a new tube. The extra 10% was later used in a bicinchoninic acid (BCA) assay to measure the relative protein content in each sample. Protein content derived from the BCA assay was used to normalize the CoQ measurements.
The remaining 90% of the cell suspension was mixed with glass beads and 600 µL of cold methanol containing 0.25 µM CoQ6 (CoQ6 was used to normalize for the total CoQ extracted). Cell suspensions were subjected to lysis on a vortex genie at 4 °C for 10 min. Afterward, 400 μL of cold petroleum ether was added to each tube, and vortexing was repeated for 3 min. To separate the petroleum ether and methanol phases, the tubes were centrifuged at 1100× g for 3 min, and the top (petroleum ether) phase was collected into a new tube (Tube B). Again, 400 µL of petroleum ether was added to each tube containing methanol, and the vortexing/centrifuge steps were repeated. The final top layer was collected and added to Tube B. Petroleum ether was dried under a stream of argon gas, and dried lipids were resuspended in 50 μL of mobile phase (78:20:2 methanol:isopropanol:ammonium acetate).

4.9. Measurement of CoQ9 by LC-MS/MS Lipidomics

LC-MS/MS Lipidomics Data Acquisition: A Vanquish Horizon UHPLC system (Thermo Scientific, Waltham, MA, USA) connected to an Exploris 240 Orbitrap mass spectrometer (Thermo Scientific, Waltham, MA, USA) was used for targeted LC-MS analysis. A Waters Acquity CSH C18 column (100 mm × 2.1 mm, 1.7 μm) was held at 35 °C with the flow rate of 0.3 mL/min for lipid separation. A Vanquish binary pump system was employed to deliver mobile phase A consisting of 5 mM ammonium acetate in ACN/H2O558 (70/30, v/v) containing 125 μL/L acetic acid, and mobile phase B consisting of 5 mM ammonium acetate in IPA/ACN (90/10, v/v) containing 125 μL/L acetic acid. The gradient was set as follows: B was at 2% for 2 min and increased to 30% over the next 3 min, then further ramped up to 50% within 1 min and to 85% over the next 14 min, and then raised to 99% over 1 min and held for 4 min before being re-equilibrated for 5 min at 2% B. Samples were ionized by a heated ESI source with a vaporizer temperature of 350 °C. Sheath gas was set to 50 units, auxiliary gas was set to 8 units, sweep gas was set to 1 unit. The ion transfer tube temperature was kept at 325 °C with a 70% RF lens. Spray voltage was set to 3500 V for positive mode. The targeted acquisition was performed with tMS2 (targeted MS2) mode: tMS2 mode was for measuring CoQ6 (m/z 591.4408, internal standard) and CoQ9 (m/z 795.6286) in positive polarity at the resolution of 15,000, isolation window of 2 m/z, normalized HCD collision energy of either 40% or stepped HCD energies of 30% and 50%, with a standard AGC target and auto maximum ion injection time.
Data Analysis: Targeted quantitative analysis of all acquired compounds was processed using TraceFinder 5.1 (Thermo Scientific, Waltham, MA, USA) with the mass accuracy of 5 ppm. The result of peak integration was manually examined.

4.10. Lipid Extraction and Intracellular Cholesterol Quantification

Cholesterol was extracted from cells with hexane–isopropanol (3:2, v/v), dried under nitrogen gas and reconstituted with buffer (0.5 M potassium phosphate, pH 7.4, 0.25 M NaCl, 25 mM cholic acid, 0.5% Triton X-100). Intracellular cholesterol levels were then quantified with the Amplex Red Cholesterol Assay Kit (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s protocol.

4.11. Sample Preparation for Electron Microscopy

C2C12 cells were grown on MatTek glass bottom dishes (P35G-1.5-14-C, MatTek, Ashland, OR, USA) and fixed in 2% glutaraldehyde + 2% paraformaldehyde solution (prepared by Electron Microscopy Lab, Berkeley, CA, USA) for 24 h. After fixation, cells and tissues were washed 3-times for 5 min in 0.1 M sodium cacodylate buffer, pH 7.4. Samples were then post-fixed in 1% osmium tetroxide + 1.6% potassium ferricyanide (KFECn) in 0.1 M sodium cacodylate buffer for 30 min, before undergoing three washes at 15 min each. Cells were then dehydrated in a serial diluted ethanol solution of 30, 50, 70, 90, and 100% for 10 min each. Samples were infiltrated with 50% Epon-Araldite resin (containing benzyldimethylamine (BDMA) accelerator), followed by 100% resin for 1 h each. Excess resin was removed from the MatTek dishes containing cells and polymerized at 60 °C for 48 h.

4.12. Transmission Electron Microscopy

Using a dissecting blade, cells embedded in resin were removed from MatTek dishes and mounted on resin-embedded blocks for sectioning. Serial sections of 70–150 nm thickness were cut on a Reichert-Jung Ultracut E microtome and set on 1 × 2-mm slot grids covered with 0.6% Formvar film. Sections were then post-stained with 1% aqueous uranyl acetate for 7 min and lead citrate for 4 min [84]. Images of cell samples were taken on an FEI Tecnai 12 transmission electron microscope (Hillsboro, CA, USA) equipped with a 2k × 2k CCD camera with a 40 Megapixel/s readout mode. Images were analyzed using ImageJ (version 1.54p) software according to the method by Lam et al. [85]. Quantification of mitochondrial morphology and mitophagy were performed double-blinded where the groups and images were randomized. Types of mitochondria were evaluated by trained staff at the UC Berkeley electron microscopy laboratory using the method described by Shults et al. [86].

4.13. Immunoblotting

Cells were washed with PBS and lysed in M Cellytic Lysis Buffer containing 1% protease inhibitor (Halt ™ Protease Inhibitor Cocktail; Thermo Scientific, Waltham, MA, USA) for 15 min with gentle vortexing. The cell lysate was centrifuged at 14,000× g for 15 min, the supernatant was collected, and the protein concentration was measured by the Bradford assay. To ensure balanced loading across conditions, the total protein concentration in the control and treatment samples were normalized to achieve an equal protein loading per well. Proteins were separated on a 4–20% Tris-polyacrylamide gradient gel (Bio-Rad, Hercules, CA, USA) and transferred onto a nitrocellulose membrane using the iBlot™ 2 Gel Transfer Device (Thermo Fisher Scientific, Waltham, MA, USA). Membranes were blocked in Tris-buffered saline with 0.1% Tween (TBST) + 5% milk for 2 h to minimize non-specific antibody binding. Membranes were then incubated with primary antibodies: TOMM40 (E6Q3Z), TOMM22 (E3F4M), TOMM20 (D8T4N), VDAC1 (D73D12), MFN2 (D1E9), OPA1 (D6U6N), DRP1 (D6C7), GAPDH (14C10) rabbit monoclonal antibodies, and PARKIN (Prk8) mouse monoclonal antibody (Cell Signal) diluted 1:1000 (v/v) in TBST overnight on a rotating platform at 4 °C. After washing in TBST, membranes were incubated with secondary antibodies, anti-rabbit IgG (7074) and anti-mouse IgG (7076), HRP-linked antibodies (Cell Signal, Danvers, MA, USA) at 1:2500 (v/v) dilution, for 30 min before a last series of washes. SuperSignal™ West Pico PLUS Chemiluminescent Substrate (Thermo Fisher Scientific, Waltham, MA, USA) was added to the membrane to visualize proteins [87].

4.14. RT-qPCR and mtDNA Copy Number

RNA was extracted from cells using the RNeasy Mini Qiacube Kit with the Qiacube Connect (Qiagen, Venlo, The Netherlands) according to the manufacturer’s protocol. cDNA synthesis from total RNA was performed using High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems, Waltham, MA, USA). Primers obtained from Elim Biopharmaceuticals were run with SYBR™ Green qPCR Master Mix (Thermo Fisher Scientific, Waltham, MA, USA) on an ABI PRISM 7900 Sequence Detection System to quantify the mRNA transcript levels. RT-qPCR primers used in this study are listed in Table S1. The mean value of triplicates for each sample was normalized to GAPDH as the housekeeping gene. The delta delta Ct method was used to calculate 2-fold change in mRNA expression compared with the control group.
Total DNA was isolated from C2C12 cells using the DNeasy Blood and Tissue Kit (Qiagen, Venlo, The Netherlands). qPCR was performed with SYBR™ Green qPCR Master Mix (Thermo Fisher Scientific, Waltham, MA, USA) on an ABI PRISM 7900 Sequence Detection System according to the protocol outlined by Quiros et al. [30]. Primers for mouse mtDNA (mMitoF1: 5′-CTAGAAACCCCGAAACCAAA-3′, mMitoR1: 5′-CCAGCTATCACCAAGCTCGT-3′) and mouse B2M (mB2MF1: 5′-ATGGGAAGCCGAACATACTG-3′, mB2MR1: 5′CAGTCTCAGTGGGGGTGAAT-3′) were used to amplify mtDNA and nuclear DNA, respectively. mtDNA copy number was determined by normalizing mtDNA to nuclear DNA. The delta delta Ct method was used to calculate fold change in mtDNA copy number.

4.15. Statistical Analysis

All data are presented as the mean ± standard error of the mean (SEM). N-values in the figures refer to biological replicates, and at least three replicates were conducted per condition and experiment. p-values were calculated using Student’s t-tests for two groups. To compare more than two groups, one-way analysis of variance (ANOVA) or Welch and Brow–Forsythe ANOVA with Tukey’s post hoc test were used. Analyses were performed using GraphPad Prism 9 software (GraphPad Software, Inc., San Diego, USA). p < 0.05 was considered statistically significant.

5. Conclusions

This study demonstrates that TOMM40 and TOMM22, major members of the TOM complex, have key roles in maintaining mitochondrial function, composition, and dynamics in skeletal muscle cells. We further highlight that downregulation of these genes by simvastatin treatment is in part responsible for the mitochondrial phenotypes induced in these skeletal muscle cells, in which the overexpression of TOMM40 and TOMM22 restored markers of mitochondrial dynamics and morphology. Furthermore, the overexpression of both TOMM40 and BCAP31 was required to restore simvastatin-induced mitochondrial dysfunction in vitro. This study also demonstrated reductions in mitochondrial cholesterol and CoQ10 content with statin exposure of skeletal muscle cells but that these effects were independent of changes in the expression of genes of the TOM complex. We conclude that, since mitochondrial dysfunction is known to have a key role in mediating SAMS, our findings suggest a plausible mechanism for the contribution of statin-induced suppression of TOMM40 and TOMM22 to their pathogenesis.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms262210977/s1.

Author Contributions

N.V.Y. and R.M.K. designed the experiments. N.V.Y., S.R., R.G., and J.Y.C. performed the experiments. N.V.Y. and S.R. analyzed the data. N.V.Y. and R.M.K. wrote the manuscript. D.J.P. and E.T. reviewed the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by a gift from the Jordan Family Foundation, NIH R35GM131795, NIH T32 DK007120, and funds from the BJC Investigator Program.

Institutional Review Board Statement

All animal experiments were reviewed and approved on 25 April 2023 by the Institutional Animal Care and Use Committee (IACUC) at the University of California San Francisco (approval number: AN196014-01B).

Informed Consent Statement

Not applicable.

Data Availability Statement

The original contributions presented in this study are included in the article/Supplementary Materials. Further inquiries can be directed to the corresponding author.

Acknowledgments

We thank Reena Zalpuri and Danielle Jorgens at the University of California, Berkeley, Electron Microscopy Laboratory for their advice and assistance in electron microscopy sample preparation and data collection. We thank Tommy Tran for his assistance with the Agilent Seahorse XFe96 Extracellular Flux Analyzer and qPCR. We thank Marisa Medina for the use of her laboratory.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
TOMTranslocase of outer mitochondrial membrane
SAMSStatin-associated muscle symptoms
hSkMCsPrimary human skeletal muscle cells
KDKnockdown
MERCsMitochondria-ER contact sites
CoQCoenzyme Q
OCROxygen consumption rate
mitoROSMitochondrial reactive oxygen species
TEMTransmission electron microscopy

References

  1. Gidding, S.S.; Allen, N.B. Cholesterol and atherosclerotic cardiovascular disease: A lifelong problem. J. Am. Heart Assoc. 2019, 8, e012924. [Google Scholar] [CrossRef] [PubMed]
  2. Mangravite, L.M.; Wilke, R.A.; Zhang, J.; Krauss, R.M. Pharmacogenomics of statin response. Curr. Opin. Mol. Ther. 2008, 10, 555–561. [Google Scholar] [CrossRef]
  3. Taylor, B.A.; Thompson, P.D. Statin-associated muscle disease: Advantages in diagnosis and management. Neurotherapeutics 2018, 15, 1006–1017. [Google Scholar] [CrossRef]
  4. Apostolopoulou, M.; Corsini, A.; Roden, M. The role of mitochondria in statin-induced myopathy. Eur. J. Clin. Investig. 2015, 45, 745–754. [Google Scholar] [CrossRef]
  5. Ezad, S.; Cheema, H.; Collins, N. Statin-induced rhabdomyolysis: A complication of a commonly overlooked drug interaction. Oxf. Med. Case Rep. 2018, 2018, omx104. [Google Scholar] [CrossRef] [PubMed]
  6. Tomaszewski, M.; Stepien, K.M.; Tomaszewska, J.; Czuczwar, S.J. Statin-induced myopathies. Pharmacol. Rep. 2011, 63, 859–866. [Google Scholar] [CrossRef]
  7. Stroes, E.S.; Thompson, P.D.; Corsini, A.; Vladutiu, G.D.; Raal, F.J.; Ray, K.K.; Roden, M.; Stein, E.; Tokgozoglu, L.; Nordestgaard, B.G.; et al. Statin-associated muscle symptoms: Impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J. 2015, 36, 1012–1022. [Google Scholar] [CrossRef]
  8. Ramachandran, R.; Wierzbicki, A.S. Statins, muscle disease and mitochondria. J. Clin. Med. 2017, 6, 75. [Google Scholar] [CrossRef]
  9. Schirris, T.J.J.; Renkema, G.H.; Ritschel, T.; Willems, P.H.G.M.; Smeitink, J.A.M.; Russel, F.G.M. Statin-induced myopathy is associated with mitochondrial complex III inhibition. Cell Met. 2015, 22, 399–407. [Google Scholar] [CrossRef]
  10. Bouitbir, J.; Charles, A.L.; Laguna, A.E.; Kindo, M.; Daussin, F.; Auqerx, J.; Piquard, F.; Geny, B.; Zoll, J. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: A ‘mitohormesis’ mechanism involving reactive oxygen species and PGC-1. Eur. Heart J. 2012, 33, 1397–1407. [Google Scholar] [CrossRef] [PubMed]
  11. Kauffman, P.; Torok, M.; Zahno, A.; Waldhauser, K.M.; Brecht, K.; Krahendbuhl, S. Toxicity of statins on rat skeletal muscle mitochondrial. Cell. Mol. Life Sci. 2006, 63, 2415–2425. [Google Scholar] [CrossRef]
  12. Vaughan, R.A.; Carvia-Smith, R.; Bisoffi, M.; Conn, C.A.; Trujillo, K.A. Ubiquinol rescues simvastatin-suppression of mitochondrial content, function and metabolism: Implications for statin-induced rhabdomyolysis. Eur. J. Pharmacol. 2013, 711, 1–9. [Google Scholar] [CrossRef]
  13. Capizzi, J.A.; Grimaldi, A.S.; Clarkson, P.M.; Cole, S.M.; Keadle, J. Effect of statins on skeletal muscle function. Circulation 2013, 127, 96–103. [Google Scholar] [CrossRef]
  14. Stringer, H.A.; Sohi, G.K.; Maguire, J.A.; Cote, H.C. Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy. J. Neurol. Sci. 2013, 325, 142–147. [Google Scholar] [CrossRef] [PubMed]
  15. Ballard, K.D.; Parker, B.A.; Thompson, P.D. Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance. Atherosclerosis 2013, 230, 121–124. [Google Scholar] [CrossRef]
  16. Nakahara, K.; Kuriyama, M.; Sonoda, Y.; Yoshidome, H.; Nakagawa, H.; Fujiyama, J. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: A pathological, electrophysiological, and biochemical study. Toxicol. Appl. Pharmacol. 1998, 152, 99–106. [Google Scholar] [CrossRef]
  17. Grunwald, S.A.; Popp, O.; Haafke, S.; Jedraszczak, N.; Grieben, U.; Saar, K.; Patone, G.; Kress, W.; Steinhagen-Thiessen, E.; Dittmar, G.; et al. Statin-induced myopathic changes in primary human muscle cells and reversal by a prostaglandin F2 alpha analogue. Sci. Rep. 2020, 10, 3158. [Google Scholar] [CrossRef] [PubMed]
  18. Gottzchalk, W.K.; Lutz, M.W.; He, Y.T.; Saunders, A.M.; Burns, D.K.; Roses, A.D.; Chiba-Falek, O. The broad impact of TOM40 on neurodegenerative diseases in aging. J. Park. Dis. Alzheimers Dis. 2014, 1, 12. [Google Scholar]
  19. Theusch, E.; Kim, K.; Stevens, K.; Smith, J.D.; Chen, Y.; Rotter, J.I.; Nickerson, D.A.; Medina, M.W. Statin-induced expression change of INSIG1 in lymphoblastoid cell lines correlates with plasma triglyceride statin response in a sex-specific manner. Pharmacogenom. J. 2017, 17, 222–229. [Google Scholar] [CrossRef]
  20. Pitt, A.S.; Buchanan, S.K. A biochemical and structural understanding of TOM complex interactions and implications for human health and disease. Cells 2021, 10, 1164. [Google Scholar] [CrossRef]
  21. Truscott, K.N.; Voos, W.; Frazier, A.E.; Lind, M.; Li, Y.; Geissler, A.; Dudek, J.; Muller, H.; Sickmann, A.; Meyer, H.E. A J-protein is an essential subunit of the presequence translocase-associated protein import motor of mitochondria. J. Cell Biol. 2003, 163, 707–713. [Google Scholar] [CrossRef]
  22. Guan, Z.; Yan, L.; Wang, Q.; Qi, L.; Hong, S.; Gong, Z.; Yan, C.; Yin, P. Structural insights into assembly of human mitochondrial translocase TOM complex. Cell Discov. 2021, 7, 22. [Google Scholar] [CrossRef]
  23. Ahting, U.; Thieffry, M.; Engelhardt, H.; Hegerl, R.; Neupert, W.; Nussberger, S. TOM40, the pore-forming component of the protein-conducting TOM channel in the outer membrane of mitochondria. J. Cell Biol. 2001, 153, 1151–1160. [Google Scholar] [CrossRef]
  24. Yang, N.V.; Chao, J.Y.; Garton, K.A. TOMM40 regulates hepatocellular and plasma lipid metabolism via an LXR-dependent pathway. Mol. Metab. 2024, 90, 102056. [Google Scholar] [CrossRef]
  25. Namba, T. BAP31 regulates mitochondrial function via interaction with Tom40 within ER-mitochondria contact sites. Sci. Adv. 2019, 5, eaaw1386. [Google Scholar] [CrossRef]
  26. Larsen, M.C.; Lee, J.; Jorgensen, J.S.; Jefcoate, C.R. STARD1 functions in mitochondrial cholesterol metabolism and nascent HDL formation. Gene expression and molecular mRNA imaging show novel splicing and a 1:1 mitochondrial association. Front. Endocrinol. 2020, 11, 559674. [Google Scholar] [CrossRef]
  27. Lazarou, M.; Jin, S.M.; Kane, L.A.; Youle, R.J. Role of PINK1 binding to the TOM complex and alternate intracellular membranes in recruitment and activation of the E3 ligase Parkin. Dev. Cell 2012, 22, 320–333. [Google Scholar] [CrossRef]
  28. Mullen, P.J.; Luscher, B.; Scharnagl, H.; Krahenbuhl, S.; Brecht, K. Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. Biochem. Pharmacol. 2010, 79, 1200–1209. [Google Scholar] [CrossRef] [PubMed]
  29. Martin, L.A.; Kennedy, B.E.; Karten, B. Mitochondrial cholesterol: Mechanisms of import and effects on mitochondrial function. J. Bioenerg. Biomembr. 2016, 48, 137–151. [Google Scholar] [CrossRef] [PubMed]
  30. Quiros, P.M.; Goyal, A.; Auwerx, J. Analysis of mtDNA/nDNA ratio in mice. Curr. Protoc. Mouse Biol. 2017, 7, 47–54. [Google Scholar] [CrossRef] [PubMed]
  31. Stefely, J.A.; Pagliarini, D.J. Biochemistry of mitochondrial Coenzyme Q biosynthesis. Trends Biochem. Sci. 2017, 42, 824–843. [Google Scholar] [CrossRef]
  32. Weibel, E.R.; Kistler, G.S.; Scherle, W.F. Practical stereological methods for morphometric cytology. J. Cell Biol. 1966, 301, 23–38. [Google Scholar] [CrossRef]
  33. Panajatovic, M.V.; Singh, F.; Roos, N.J.; Duthaler, U.; Handschin, C.; Krähenbühl, S.; Bouitbir, J. PGC-1α plays a pivotal role in simvastatin-induced exercise impairment in mice. Acta Physiol. 2019, 228, e13402. [Google Scholar] [CrossRef] [PubMed]
  34. Lemasters, J.J. Variants of mitochondrial autophagy: Types 1 and 2 mitophagy and micromitophagy (Type 3). Redox Biol. 2014, 2, 749–754. [Google Scholar] [CrossRef]
  35. Billing, O.; Kao, G.; Naredi, P. Mitochondrial function is required for secretion of DAF-28/insulin in C. elegans. PLoS ONE. 2011, 6, e14507. [Google Scholar] [CrossRef] [PubMed]
  36. Bertolini, G.; Ferrando-Miguel, R.; Jacoupy, M.; Traver, S.; Grenier, K.; Greene, A.W.; Daupin, A.; Waharte, F.; Bayot, A.; Salamero, J. The TOMM machinery is a molecular switch in PINK1 and PARK2/PARKIN-dependent mitochondrial clearance. Autophagy 2013, 9, 1801–1817. [Google Scholar] [CrossRef]
  37. Yang, W.; Shin, H.Y.; Cho, H.; Chung, J.Y.; Lee, E.; Kim, J.H.; Kang, E.S. TOM40 inhibitos ovarian cancer cell growth by modulating mitochondrial function including intracellular ATP and ROS levels. Cancers 2020, 12, 1329. [Google Scholar] [CrossRef] [PubMed]
  38. Lee, T.S.; Goh, L.; Chong, M.S.; Chua, S.M.; Chen, G.B.; Feng, L.; Lim, W.S.; Chan, M.; Ng, T.P.; Krishnan, K.R. Downregulation of TOMM40 expression in the blood of Alzheimer disease subjects compared with matched controls. J. Psychiatr. Res. 2012, 46, 828–830. [Google Scholar] [CrossRef]
  39. Bogorodskiy, A.; Okhrimenko, I.; Burkatovskii, D.; Jakobs, P.; Maslov, I.; Gordeliy, V.; Dencher, N.A.; Gensch, T.; Voos, W.; Altschmied, J.; et al. Role of mitochondrial protein import in age-related neurodegenerative and cardiovascular disease. Cells 2021, 10, 3528. [Google Scholar] [CrossRef]
  40. Curado, S.; Ober, E.A.; Walsh, S.; Cortes-Hernandez, P.; Verkade, H.; Koehler, C.M.; Stainier, D.Y.R. The mitochondrial import gene Tomm22 is specifically required for hepatocyte survival and provides a liver regeneration model. Dis. Model. Mech. 2010, 3, 486–495. [Google Scholar] [CrossRef]
  41. Wu, J.; Choi, T.Y.; Shin, D. Tomm22 knockdown-mediated hepatocyte damages elicit both the formation of hybrid hepatocytes and biliary conversion to hepatocytes in zebrafish larvae. Gene Expr. 2017, 17, 237–249. [Google Scholar] [CrossRef]
  42. Middelberg, R.P.S.; Ferreira, M.A.R.; Henders, A.K.; Heath, A.C.; Madden, P.A.F.; Montgomery, G.W.; Martin, N.G.; Whitfield, J.B. Genetic variants in LPL, OASL and TOMM40/APOE-C1-C2-C4 genes are associated with multiple cardiovascular-related traits. BMC Med. Genet. 2011, 12, 123. [Google Scholar] [CrossRef] [PubMed]
  43. Olson, R.E.; Bentley, R.; Aiyar, A.S.; Dialameh, G.H.; Gold, P.H.; Ramsey, V.G.; Springer, C.M. Benzoate derivatives as intermediates in the biosynthesis of coenzyme Q in the rat. J. Biol. Chem. 1963, 238, 3146–3148. [Google Scholar] [CrossRef]
  44. Tai, J.; Guerra, R.M.; Rogers, S.W.; Fang, Z.; Muehlbauer, L.K.; Shishkova, E.; Overmyer, K.A.; Coon, J.J.; Pagliarini, D.J. Hem25p is a mitochondrial IPP transporter. bioRxiv 2023. [Google Scholar] [CrossRef] [PubMed]
  45. Kalen, A.; Appelkvist, E.L.; Chojnacki, T.; Dallner, G. Nonaprenyl-4-hydroxybenzoate transferase, an enzyme involved in ubiquinone biosynthesis, in the endoplasmic reticulum-Golgi system of rat liver. J. Biol. Chem. 1990, 265, 1158–1164. [Google Scholar] [CrossRef] [PubMed]
  46. Guerra, R.M.; Pagliarini, D.J. Coenzyme Q biochemistry and biosynthesis. Trends Biochem. Sci. 2023, 48, 463–476. [Google Scholar] [CrossRef]
  47. Fernandez-Ayala, D.J.; Brea-Calvo, G.; Lopez-Lluch, G. Coenzyme Q distribution in HL-60 human cells depends on the endomembrane system. Biochim. Biophys. Acta 2005, 1713, 129–137. [Google Scholar] [CrossRef]
  48. Tosi, G.; Paoli, A.; Zuccolotto, G. Cancer cell stiffening via CoQ10 and UBIAD1 regulates ECM signaling and ferroptosis in breast cancer. Nat. Commun. 2024, 15, 8214. [Google Scholar] [CrossRef]
  49. Liesa, M.; Palacin, M.; Zorzano, A. Mitochondrial dynamics in mammalian health and disease. Physiol. Rev. 2009, 89, 799–845. [Google Scholar] [CrossRef]
  50. Ferree, A.; Shirihai, O. Mitochondrial dynamics: The intersection of form and function. Adv. Exp. Med. Biol. 2012, 748, 13–40. [Google Scholar]
  51. Caldeira, D.A.F.; Weiss, D.J.; Cruz, F.F. Mitochondria in focus: From function to therapeutic strategies in chronic lung diseases. Front. Immunol. 2021, 12, 78074. [Google Scholar] [CrossRef]
  52. Nasca, A.; Scotton, C.; Ghezzi, D. Recessive mutations in MSTO1 cause mitochondrial dynamics impairment, leading to myopathy and ataxia. Hum. Mutat. 2017, 38, 970–977. [Google Scholar] [CrossRef]
  53. Yu, R.; Lendahl, U.; Nister, M.; Zhao, J. Regulation of mammalian mitochondrial dynamics: Opportunities and challenges. Front. Endocrinol. 2020, 11, 374. [Google Scholar] [CrossRef] [PubMed]
  54. Zhao, J.; Lendahl, U.; Nister, M. Regulation of mitochondrial dynamics: Convergences and divergences between yeast and vertebrates. Cell. Mol. Life Sci. 2013, 70, 951076. [Google Scholar] [CrossRef] [PubMed]
  55. Mishra, P.; Chan, D.C. Mitochondrial dynamics and inheritance during cell division, development and disease. Nat. Rev. Mol. Cell Biol. 2014, 15, 634–646. [Google Scholar] [CrossRef]
  56. Roy, M.; Reddy, P.H.; Iijima, M.; Sesaki, H. Mitochondrial division and fusion in metabolism. Curr. Opin. Cell. Biol. 2015, 33, 111–118. [Google Scholar] [CrossRef]
  57. Wai, T.; Langer, T. Mitochondrial dynamics and metabolic regulation. Trends Endocrinol. Metab. 2016, 27, 105–117. [Google Scholar] [CrossRef]
  58. Song, M.; Mihara, K.; Chen, Y.; Scorrano, L.; Dorn, G.W., 2nd. Mitochondrial fission and fusion factors reciprocally orchestrate mitophagic culling in mouse hearts and cultured fibroblasts. Cell Metab. 2015, 21, 273–286. [Google Scholar] [CrossRef]
  59. Herrera-Cruz, M.S.; Simmen, T. Of yeast, mice and men: MAMs come in two flavors. Biol. Direct. 2017, 12, 3. [Google Scholar] [CrossRef]
  60. Zaman, M.; Shutt, T.E. The role of impaired mitochondrial dynamics in MFN2-mediated pathology. Front. Cell Dev. Biol. 2022, 10, 858286. [Google Scholar] [CrossRef] [PubMed]
  61. Matsuda, N.; Sato, S.; Shiba, K.; Okatsu, K.; Saisho, K.; Gautier, C.A.; Sou, Y.S.; Saiki, S.; Kawajiri, S.; Sato, F. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activate latent Parkin for mitophagy. J. Cell Biol. 2010, 189, 211–221. [Google Scholar] [CrossRef]
  62. Raimi, O.G.; Ojha, H.; Ehses, K.; Dederer, V.; Lange, S.M.; Rivera, C.P.; Deegan, T.D.; Chen, Y.; Wightman, M.; Toth, R.; et al. Mechanism of human PINK1 activation at the TOM complex in a reconstituted system. Sci. Adv. 2024, 10, eadn7191. [Google Scholar] [CrossRef]
  63. Okatsu, K.; Uno, M.; Koyano, F.; Go, E.; Kimura, M.; Oka, T.; Tanaka, K.; Matsuda, N. A dimeric PINK1-containing complex on depolarized mitochondria stimulates Parkin recruitment. J. Biol. Chem. 2013, 288, 36372–36384. [Google Scholar] [CrossRef]
  64. Hasson, S.A.; Kane, L.A.; Yamano, K.; Huang, C.H.; Sliter, D.A.; Buehler, E.; Wang, C.; Heman-Ackah, S.M.; Hessa, T.; Guha, R.; et al. High-content genome-wide RNAi screens identify regulators of Parkin upstream of mitophagy. Nature 2013, 504, 291–295. [Google Scholar] [CrossRef]
  65. Yamano, K.; Yatsukawa, Y.; Esaki, M.; Hobbs, A.E.A.; Jensen, R.E.; Endo, T. Tom20 and Tom22 share the common signal recognition pathway in mitochondrial protein import. J. Biol. Chem. 2008, 283, 3799–3807. [Google Scholar] [CrossRef] [PubMed]
  66. Wu, S.; Zhou, F.; Zhang, Z.; Xing, D. Mitochondrial oxidative stress causes mitochondrial fragmentation via differential modulation of mitochondrial fission-fusion proteins. FEBS J. 2011, 278, 941–954. [Google Scholar] [CrossRef] [PubMed]
  67. Srinivasan, S.; Guha, M.; Kashina, A.; Avadhani, N.G. Mitochondrial dysfunction and mitochondrial dynamics-The cancer connection. Biochim. Biophys. Acta Bioenerg. 2017, 1858, 602–614. [Google Scholar] [CrossRef]
  68. Cirigliano, A.; Amelina, A.; Bigerali, B.; Macone, A.; Mozzetta, C.; Bianchi, M.M.; Mori, M.; Botta, B.; Pick, E.; Negri, R.; et al. Statins interfere with the attachment of S. cerevisiae mtDNA to the inner mitochondrial membrane. J. Enzym. Inhib. Med. Chem. 2020, 35, 129–137. [Google Scholar] [CrossRef]
  69. Broniarek, I.; Dominiak, K.; Galganski, L.; Jarmuszkiewicz, W. The influence of statins on the anaerobic metabolism of endothelial cells. Int. J. Mol. Sci. 2020, 21, 1485. [Google Scholar] [CrossRef]
  70. Mollazadeh, H.; Tavana, E.; Fanni, G.; Bo, S.; Banach, M.; Pirro, M.; Haehling, S.; Jamialahmadi, T.; Sahebkar, A. Effects of statins on mitochondrial pathways. J. Cachexia Sarcop. Muscle 2021, 12, 237–251. [Google Scholar] [CrossRef] [PubMed]
  71. Youle, R.J.; van der Bliek, A.M. Mitochondrial fission, fusion, and stress. Science 2012, 337, 1062–1065. [Google Scholar] [CrossRef]
  72. Manczak, M.; Calking, M.J.; Reddy, P.H. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: Implications for neuronal damage. Hum. Mol. Genet. 2011, 20, 2495–2509. [Google Scholar] [CrossRef] [PubMed]
  73. Fares, K.; Abd-El-Hamid, H.; Youssef, A.; Rafla, M. Statin-induced myopathy in muscles of lower limb with special reference to gastrocnemius muscle in albino rats. QJM 2018, 111, hcy200-082. [Google Scholar] [CrossRef]
  74. Huang, X.; Pan, C.H.; Yin, F.; Peng, J.; Yang, L. The role of estrogen in mitochondrial disease. Cell. Mol. Neurobiol. 2025, 45, 68. [Google Scholar] [CrossRef] [PubMed]
  75. Farhat, F.; Amerand, A.; Simon, B.; Guegueniat, N.; Moisan, C. Gender-dependent differences of mitochondrial function and oxidative stress in rat skeletal muscle at rest and after exercise training. Redox Rep. 2017, 22, 508–514. [Google Scholar] [CrossRef]
  76. Burman, J.L.; Pickles, S.; Wang, C.; Sekine, S.; Vargas, J.N.S.; Zhang, Z.; Youle, A.M.; Nezich, C.L.; Wu, X.; Hammer, J.A.; et al. Mitochondrial fission facilitates the selective mitophagy of protein aggregates. J. Cell Biol. 2017, 216, 3231–3247. [Google Scholar] [CrossRef]
  77. Zaleski, A.L.; Taylor, B.A.; Thompson, P.D. Coenzyme Q10 as treatment for statin-associated muscle symptoms—A good idea, but…. Adv. Nutr. 2018, 9, 519S–523S. [Google Scholar] [CrossRef]
  78. Iwasawa, R.; Mahul-Mellier, A.L.; Datler, C.; Pazarentzos, E.; Grimm, S. Fis1 and Bap31 bridge the mitochondria-ER interface to establish a platform for apoptosis induction. EMBO J. 2011, 30, 556–568. [Google Scholar] [CrossRef]
  79. Namba, T.; Tian, F.; Chu, K.; Hwang, S.Y.; Yoon, K.W.; Byun, S.; Hiraki, M.; Mandinova, A.; Lee, S.W. CDIP1-BAP31 complex transduces apoptotic signals from endoplasmic reticulum to mitochondria under endoplasmic reticulum stress. Cell Rep. 2013, 5, 331–339. [Google Scholar] [CrossRef]
  80. Zhao, J.; Liu, T.; Jin, S.; Wang, X.; Qu, M.; Uhlen, P.; Tomilin, N.; Shupliakov, O.; Lendahl, U.; Nister, M. Human MIEF1 recruits Drp1 to mitochondrial outer membranes and promotes mitochondrial fusion rather than fission. EMBO J. 2011, 30, 2762–2778. [Google Scholar] [CrossRef]
  81. Brown, M.S.; Faust, J.R.; Goldstein, J.L.; Kaneko, I.; Endo, A. Induction of 3-hydrocy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J. Biol. Chem. 1978, 253, 1121–1128. [Google Scholar] [CrossRef]
  82. Kauffman, M.E.; Kauffman, M.K.; Kassim, T.; Zhu, H.; Trush, M.A.; Jia, Z.; Li, Y.R. MitoSOX-based flow cytometry for detecting mitochondrial ROS. React. Oxyg. Species 2016, 2, 361–370. [Google Scholar] [CrossRef]
  83. Wettmarshausen, J.; Perocchi, F. Isolation of functional mitochondria from cultured cells and mouse tissues. Methods Mol. Biol. 2017, 1567, 15–32. [Google Scholar] [PubMed]
  84. Reynolds, E.S. The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J. Cell Biol. 1963, 17, 208–212. [Google Scholar] [CrossRef] [PubMed]
  85. Lam, J.; Katti, P.; Biete, M.; Mungai, M.; AshShareef, S.; Neikirk, K.; Lopez, E.G.; Vue, Z.; Christensen, T.A.; Beasley, H.K.; et al. A universal approach to analyzing transmission electron microscopy with ImageJ. Cells 2021, 10, 2177. [Google Scholar] [CrossRef]
  86. Shults, N.V.; Kanovka, S.S.; Ten Eyck, J.E.; Rybka, V.; Suzuki, Y.J. Ultrastructural changes of the right ventricular myocytes in pulmonary arterial hypertension. J. Am. Heart Assoc. 2019, 8, e011227. [Google Scholar] [CrossRef] [PubMed]
  87. Schneider, C.A.; Rasband, W.S.; Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 2012, 9, 671–675. [Google Scholar] [CrossRef]
Ijms 26 10977 g001
Figure 1. Simvastatin downregulates TOMM40 and TOMM22 in both C2C12 and hSkMC skeletal muscle. Differentiated C2C12 and primary hSkMC myotubes were treated with 2 µM simvastatin for 24 h. (A) A schematic diagram of the mammalian TOM complex, consisting of seven subunits, located in the outer mitochondrial membrane. (B) Simvastatin treatment (2 µM) downregulates Tomm40, Tomm22, Tomm20, and Tomm5 in differentiated C2C12 myotubes. (C) Simvastatin treatment (2 µM) downregulates TOMM40 and TOMM22 in hSkMC myotubes. Numeric data represent the mean ± SEM. * p < 0.05, ** p < 0.01 vs. 0 µM simvastatin by the Student’s t-test (n = 3 biological replicates).
Figure 1. Simvastatin downregulates TOMM40 and TOMM22 in both C2C12 and hSkMC skeletal muscle. Differentiated C2C12 and primary hSkMC myotubes were treated with 2 µM simvastatin for 24 h. (A) A schematic diagram of the mammalian TOM complex, consisting of seven subunits, located in the outer mitochondrial membrane. (B) Simvastatin treatment (2 µM) downregulates Tomm40, Tomm22, Tomm20, and Tomm5 in differentiated C2C12 myotubes. (C) Simvastatin treatment (2 µM) downregulates TOMM40 and TOMM22 in hSkMC myotubes. Numeric data represent the mean ± SEM. * p < 0.05, ** p < 0.01 vs. 0 µM simvastatin by the Student’s t-test (n = 3 biological replicates).
Ijms 26 10977 g001
Ijms 26 10977 g002
Figure 2. TOMM40 and TOMM22 knockdown decreases the mitochondrial oxygen consumption rate and promotes mitochondrial superoxide production. (A) Schematic illustration of the two-step transfection and differentiation experiment in C2C12 cells in vitro. (B) Confirmation of Tomm40 (T40) and Tomm22 (T22) KD in C2C12 myotubes by ~92% and ~85%, respectively, measured with qPCR (n = 3 biological replicates). (C) Oxygen consumption rates of C2C12 myotubes transfected with Tomm40 and Tomm22 siRNAs vs. NTC were quantified using the Seahorse 96e Extracellular Flux Analyzer. With the addition of oligomycin, FCCP, and Antimycin A + Rotenone, basal respiration, ATP production, and maximal respiration were quantified. (D–F) The same experiment carried out in C2C12 cells (C,D) was conducted in primary hSkMCs. (G) Mitochondrial superoxide production with Tomm40 and Tomm22 KD in C2C12 cells was quantified by MitoSOX fluorescence probe. All values were normalized to protein concentration by the Bradford assay. All graphical and numeric data represent the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. NTC. One-way ANOVA, with Tukey’s post hoc test to identify differences between groups (unless specified, n = 4–6 biological replicates).
Figure 2. TOMM40 and TOMM22 knockdown decreases the mitochondrial oxygen consumption rate and promotes mitochondrial superoxide production. (A) Schematic illustration of the two-step transfection and differentiation experiment in C2C12 cells in vitro. (B) Confirmation of Tomm40 (T40) and Tomm22 (T22) KD in C2C12 myotubes by ~92% and ~85%, respectively, measured with qPCR (n = 3 biological replicates). (C) Oxygen consumption rates of C2C12 myotubes transfected with Tomm40 and Tomm22 siRNAs vs. NTC were quantified using the Seahorse 96e Extracellular Flux Analyzer. With the addition of oligomycin, FCCP, and Antimycin A + Rotenone, basal respiration, ATP production, and maximal respiration were quantified. (D–F) The same experiment carried out in C2C12 cells (C,D) was conducted in primary hSkMCs. (G) Mitochondrial superoxide production with Tomm40 and Tomm22 KD in C2C12 cells was quantified by MitoSOX fluorescence probe. All values were normalized to protein concentration by the Bradford assay. All graphical and numeric data represent the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. NTC. One-way ANOVA, with Tukey’s post hoc test to identify differences between groups (unless specified, n = 4–6 biological replicates).
Ijms 26 10977 g002
Ijms 26 10977 g003
Figure 3. Tomm40 and Tomm22 regulate mitochondrial cholesterol content and CoQ levels in C2C12 myotubes. (A) Subcellular fractionation was performed to isolate crude mitochondria from whole cells. (B) Total and free cholesterol levels in mitochondria isolated from C2C12 myotubes transfected with NTC, Tomm40, and Tomm22 siRNAs, singly and in combination. (C,D) In a separate experiment, after cells were transfected with siRNAs, 50 µg/mL LDL-C was added to cell media for 24 h. Total and free cholesterol were quantified in the mitochondria using the Amplex Red Cholesterol Assay. (“Ctrl” = control group, “+ LDL-C” = LDL-C treatment group) (E) OCR levels were assessed in C2C12 cells after the LDL-C addback, and (F) basal respiration and ATP production were quantified using Wave Desktop 2.6 software (n = 10–12 biological replicates). (G) Total CoQ from isolated mitochondria of NTC, Tomm40, Tomm22, and Tomm22/40 KD C2C12 cells were quantified by LC-MS/MS. All values were normalized to protein concentration, measured by BCA. All graphical and numeric data represent the mean ± SEM * p < 0.05, ** p < 0.01 vs. NTC (without LDL-C addback) by the Welch and Brown–Forsythe ANOVA or one-way ANOVA, with Tukey’s post hoc test to identify differences between groups (unless specified, n = 3–6 biological replicates).
Figure 3. Tomm40 and Tomm22 regulate mitochondrial cholesterol content and CoQ levels in C2C12 myotubes. (A) Subcellular fractionation was performed to isolate crude mitochondria from whole cells. (B) Total and free cholesterol levels in mitochondria isolated from C2C12 myotubes transfected with NTC, Tomm40, and Tomm22 siRNAs, singly and in combination. (C,D) In a separate experiment, after cells were transfected with siRNAs, 50 µg/mL LDL-C was added to cell media for 24 h. Total and free cholesterol were quantified in the mitochondria using the Amplex Red Cholesterol Assay. (“Ctrl” = control group, “+ LDL-C” = LDL-C treatment group) (E) OCR levels were assessed in C2C12 cells after the LDL-C addback, and (F) basal respiration and ATP production were quantified using Wave Desktop 2.6 software (n = 10–12 biological replicates). (G) Total CoQ from isolated mitochondria of NTC, Tomm40, Tomm22, and Tomm22/40 KD C2C12 cells were quantified by LC-MS/MS. All values were normalized to protein concentration, measured by BCA. All graphical and numeric data represent the mean ± SEM * p < 0.05, ** p < 0.01 vs. NTC (without LDL-C addback) by the Welch and Brown–Forsythe ANOVA or one-way ANOVA, with Tukey’s post hoc test to identify differences between groups (unless specified, n = 3–6 biological replicates).
Ijms 26 10977 g003
Ijms 26 10977 g004
Figure 4. TOMM40 and TOMM22 knockdown, singly and in combination, impairs mitochondrial dynamics in skeletal myotubes. (A) TEM micrographs of NTC, Tomm40, Tomm22, and Tomm22/40 KD in C2C12 cells. Arrowheads indicate mitochondrial fission events. Analysis of mitochondrial morphology using ImageJ software: (B) average mitochondrial length (nm) and (C) average mitochondrial width (nm). (n = 10–15 cells). (D) Mitochondrial fission (Fis1/FIS1, Drp1/DNM1L) and fusion (Mfn2/MFN2, Opa1/OPA1) markers were quantified by qPCR in NTC, Tomm22, Tomm40, and Tomm22/40 KD C2C12 cells. (E) The experiment was conducted as in (D) but with hSkMCs (n = 3 biological replicates). (F) Mitochondrial density was quantified using a MitoTracker™ Deep Red FM fluorescence probe to measure the average fluorescence intensity and normalized to protein concentration by the Bradford assay (n = 10–12 biological replicates). (G) Relative mtDNA copy number levels were quantified and normalized to the B2m transcript levels (nuclear DNA) by qPCR in siRNA transfected C2C12 cells (n = 3 biological replicates). All graphical and numeric data represent the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. NTC. One-way ANOVA, with Tukey’s post hoc test to identify differences between groups.
Figure 4. TOMM40 and TOMM22 knockdown, singly and in combination, impairs mitochondrial dynamics in skeletal myotubes. (A) TEM micrographs of NTC, Tomm40, Tomm22, and Tomm22/40 KD in C2C12 cells. Arrowheads indicate mitochondrial fission events. Analysis of mitochondrial morphology using ImageJ software: (B) average mitochondrial length (nm) and (C) average mitochondrial width (nm). (n = 10–15 cells). (D) Mitochondrial fission (Fis1/FIS1, Drp1/DNM1L) and fusion (Mfn2/MFN2, Opa1/OPA1) markers were quantified by qPCR in NTC, Tomm22, Tomm40, and Tomm22/40 KD C2C12 cells. (E) The experiment was conducted as in (D) but with hSkMCs (n = 3 biological replicates). (F) Mitochondrial density was quantified using a MitoTracker™ Deep Red FM fluorescence probe to measure the average fluorescence intensity and normalized to protein concentration by the Bradford assay (n = 10–12 biological replicates). (G) Relative mtDNA copy number levels were quantified and normalized to the B2m transcript levels (nuclear DNA) by qPCR in siRNA transfected C2C12 cells (n = 3 biological replicates). All graphical and numeric data represent the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. NTC. One-way ANOVA, with Tukey’s post hoc test to identify differences between groups.
Ijms 26 10977 g004
Ijms 26 10977 g005
Figure 5. TOMM40 and TOMM22 knockdown, singly and in combination, promotes mitochondrial damage and mitophagy in skeletal muscle in vitro and in vivo. (A) TEM micrographs of C2C12 myotubes representing types 1 (healthy; A1 image of NTC), 2 (unhealthy; A2 image of Tomm40 KD), and 3 (damaged/ruptured; A3 image of Tomm22/40 KD) mitochondria (scale bars = 1 μm; inset scale bars = 200 nm). (B) Analysis of mitochondrial morphology and damage in NTC vs. KD C2C12 cells. Bar graph represents percent of cells exhibiting type 1 mitochondria. (C) Bar graph represents the percent of types 2 and 3 mitochondria in NTC vs. KD C2C12 cells (for 5B, C, and D: n = 10–15 cells, number of mitochondria assessed per cell > 200). (D) Percent of mitophagosomes per total number of mitochondria per cell, identified from the TEM images (n = 10–15 cells). (E) mRNA transcript levels of PINK1 and PRKN (mitophagy) were quantified using qPCR in NTC vs. KD hSkMCs (n = 3 biological replicates). (F) Representative Western blot of PRKN protein expression in hSkMCs compared with GAPDH control. (G) mRNA transcript levels of Tomm40 (~50% knockdown) were quantified in the gastrocnemius skeletal muscle of male mice injected with AAV8 scrambled vs. Tomm40 shRNA (n = 6/group). (H) Representative TEM images of gastrocnemius muscle samples from scrambled vs. Tomm40 shRNA (n = 6/group) male mice. (I) Bar graph represents the average number of mitochondria within a surface area of 36 µm2, (J) length of intermyofibrillar mitochondria (as seen in the TEM images), (K) length of sarcolemnal mitochondria, and (L) percent of ruptured mitochondria per 36 µm2. All graphical and numeric data represent the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. NTC or scrambled shRNA by one-way ANOVA, with Tukey’s post hoc test to identify differences between groups.
Figure 5. TOMM40 and TOMM22 knockdown, singly and in combination, promotes mitochondrial damage and mitophagy in skeletal muscle in vitro and in vivo. (A) TEM micrographs of C2C12 myotubes representing types 1 (healthy; A1 image of NTC), 2 (unhealthy; A2 image of Tomm40 KD), and 3 (damaged/ruptured; A3 image of Tomm22/40 KD) mitochondria (scale bars = 1 μm; inset scale bars = 200 nm). (B) Analysis of mitochondrial morphology and damage in NTC vs. KD C2C12 cells. Bar graph represents percent of cells exhibiting type 1 mitochondria. (C) Bar graph represents the percent of types 2 and 3 mitochondria in NTC vs. KD C2C12 cells (for 5B, C, and D: n = 10–15 cells, number of mitochondria assessed per cell > 200). (D) Percent of mitophagosomes per total number of mitochondria per cell, identified from the TEM images (n = 10–15 cells). (E) mRNA transcript levels of PINK1 and PRKN (mitophagy) were quantified using qPCR in NTC vs. KD hSkMCs (n = 3 biological replicates). (F) Representative Western blot of PRKN protein expression in hSkMCs compared with GAPDH control. (G) mRNA transcript levels of Tomm40 (~50% knockdown) were quantified in the gastrocnemius skeletal muscle of male mice injected with AAV8 scrambled vs. Tomm40 shRNA (n = 6/group). (H) Representative TEM images of gastrocnemius muscle samples from scrambled vs. Tomm40 shRNA (n = 6/group) male mice. (I) Bar graph represents the average number of mitochondria within a surface area of 36 µm2, (J) length of intermyofibrillar mitochondria (as seen in the TEM images), (K) length of sarcolemnal mitochondria, and (L) percent of ruptured mitochondria per 36 µm2. All graphical and numeric data represent the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. NTC or scrambled shRNA by one-way ANOVA, with Tukey’s post hoc test to identify differences between groups.
Ijms 26 10977 g005
Ijms 26 10977 g006
Figure 6. TOMM40 and BCAP31 overexpression rescues mitochondrial respiration, ATP production, and proton leak after simvastatin treatment of skeletal muscle cells. (A) OCR was measured in C2C12 cells treated with 2 µM simvastatin + empty vector or Tomm22, Tomm40, Tomm20 (T20), or Tomm20/22/40 expressing plasmids for 24–48 h. Basal respiration and ATP production determined from the OCR analysis. (B) The same experiment was conducted in hSkMCs treated with 2 µM simvastatin + empty vector or TOMM22, TOMM40, TOMM22/40 expressing plasmids for 24–48 h (n = 10–15 biological replicate). (C) mitoROS was determined in C2C12 cells by quantifying the mean mitoSOX™ fluorescence intensity and normalizing to the total protein concentration using the Bradford assay (n = 10–12 biological replicates). mRNA transcripts of (D) Bcap31 in C2C12 and (E) BCAP31 in hSkMC myotubes without and with 2 µM simvastatin was quantified by qPCR. (F–I) Basal respiration, ATP production, maximal respiration, and proton leak were analyzed from OCR recordings in C2C12 cells treated with 2 µM simvastatin + empty vector or Bcap31, Bcap31/Tomm22, or Bcap31/Tomm40 expressing plasmids for 24–48 h. (J–M) Basal respiration, ATP production, maximal respiration, and proton leak were analyzed from OCR recordings in hSkMCs treated with 2 µM simvastatin + empty vector or BCAP31, BCAP31/TOMM22, or BCAP31/TOMM40 expressing plasmids for 24–48 h. (N) Total and free cholesterol were quantified in the mitochondria of C2C12 myotubes using the Amplex Red Cholesterol Assay (n = 3–6 biological replicates). (O) Total CoQ9 was quantified from mitochondria isolated from C2C12 cells transfected with empty vector (control), 2 µM simvastatin + empty vector, Tomm22, Tomm40, Tomm20, or Tomm20/22/40 expressing plasmids (n = 3 biological replicates). All values were normalized to protein concentration by the BCA. All graphical and numeric data represent the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. EV by Welch and Brown–Forsythe or one-way ANOVA, with Tukey’s post hoc test to identify differences between groups.
Figure 6. TOMM40 and BCAP31 overexpression rescues mitochondrial respiration, ATP production, and proton leak after simvastatin treatment of skeletal muscle cells. (A) OCR was measured in C2C12 cells treated with 2 µM simvastatin + empty vector or Tomm22, Tomm40, Tomm20 (T20), or Tomm20/22/40 expressing plasmids for 24–48 h. Basal respiration and ATP production determined from the OCR analysis. (B) The same experiment was conducted in hSkMCs treated with 2 µM simvastatin + empty vector or TOMM22, TOMM40, TOMM22/40 expressing plasmids for 24–48 h (n = 10–15 biological replicate). (C) mitoROS was determined in C2C12 cells by quantifying the mean mitoSOX™ fluorescence intensity and normalizing to the total protein concentration using the Bradford assay (n = 10–12 biological replicates). mRNA transcripts of (D) Bcap31 in C2C12 and (E) BCAP31 in hSkMC myotubes without and with 2 µM simvastatin was quantified by qPCR. (F–I) Basal respiration, ATP production, maximal respiration, and proton leak were analyzed from OCR recordings in C2C12 cells treated with 2 µM simvastatin + empty vector or Bcap31, Bcap31/Tomm22, or Bcap31/Tomm40 expressing plasmids for 24–48 h. (J–M) Basal respiration, ATP production, maximal respiration, and proton leak were analyzed from OCR recordings in hSkMCs treated with 2 µM simvastatin + empty vector or BCAP31, BCAP31/TOMM22, or BCAP31/TOMM40 expressing plasmids for 24–48 h. (N) Total and free cholesterol were quantified in the mitochondria of C2C12 myotubes using the Amplex Red Cholesterol Assay (n = 3–6 biological replicates). (O) Total CoQ9 was quantified from mitochondria isolated from C2C12 cells transfected with empty vector (control), 2 µM simvastatin + empty vector, Tomm22, Tomm40, Tomm20, or Tomm20/22/40 expressing plasmids (n = 3 biological replicates). All values were normalized to protein concentration by the BCA. All graphical and numeric data represent the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. EV by Welch and Brown–Forsythe or one-way ANOVA, with Tukey’s post hoc test to identify differences between groups.
Ijms 26 10977 g006
Ijms 26 10977 g007
Figure 7. Overexpressing TOMM40 and TOMM22, singly and in combination, suppresses statin-induced mitochondrial fission and promotes fusion in skeletal muscle cells. (A) Representative TEM images of mitochondrial morphology in C2C12 cells transfected with empty vector (EV), 2 µM simvastatin + EV, and Tomm22, Tomm40, or Tomm22/40 expressing plasmids. (B,C) Using ImageJ software analysis in conjunction with the TEM images in (A), the average mitochondrial length and width (nm) were measured (n = 10–15 cells). (D) Mitochondrial fission (Fis1/FIS1, Drp1/DNM1L) and fusion (Mfn2/MFN2, Opa1/OPA1) markers were quantified by qPCR in EV and 2 µM simvastatin + EV, Tomm22, Tomm40, Tomm20, and Tomm20/22/40 (T20/22/40) overexpressing C2C12 cells. (E) The same experiment was conducted as in (D) but with hSkMCs (n = 3 biological replicates). (F) Mitochondrial density was quantified using a MitoTracker™ Deep Red FM fluorescence probe to measure the average fluorescence intensity and was normalized to protein concentration by the Bradford assay (n = 10–12 biological replicates). (G) Relative mtDNA copy number levels were quantified and normalized to the B2m transcript levels (nuclear DNA) by qPCR in siRNA transfected C2C12 cells (n = 3 biological replicates). All graphical and numeric data represent the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. One-way ANOVA, with Tukey’s post hoc test to identify differences between groups, was performed.
Figure 7. Overexpressing TOMM40 and TOMM22, singly and in combination, suppresses statin-induced mitochondrial fission and promotes fusion in skeletal muscle cells. (A) Representative TEM images of mitochondrial morphology in C2C12 cells transfected with empty vector (EV), 2 µM simvastatin + EV, and Tomm22, Tomm40, or Tomm22/40 expressing plasmids. (B,C) Using ImageJ software analysis in conjunction with the TEM images in (A), the average mitochondrial length and width (nm) were measured (n = 10–15 cells). (D) Mitochondrial fission (Fis1/FIS1, Drp1/DNM1L) and fusion (Mfn2/MFN2, Opa1/OPA1) markers were quantified by qPCR in EV and 2 µM simvastatin + EV, Tomm22, Tomm40, Tomm20, and Tomm20/22/40 (T20/22/40) overexpressing C2C12 cells. (E) The same experiment was conducted as in (D) but with hSkMCs (n = 3 biological replicates). (F) Mitochondrial density was quantified using a MitoTracker™ Deep Red FM fluorescence probe to measure the average fluorescence intensity and was normalized to protein concentration by the Bradford assay (n = 10–12 biological replicates). (G) Relative mtDNA copy number levels were quantified and normalized to the B2m transcript levels (nuclear DNA) by qPCR in siRNA transfected C2C12 cells (n = 3 biological replicates). All graphical and numeric data represent the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. One-way ANOVA, with Tukey’s post hoc test to identify differences between groups, was performed.
Ijms 26 10977 g007
Ijms 26 10977 g008
Figure 8. Overexpression of TOMM40 and TOMM22, but not TOMM20, rescues simvastatin-induced mitophagy leading to reduced mitochondrial damage. (A) TEM micrographs of mitophagosomes found in EV, 2 µM simvastatin + EV, and 2 µM simvastatin + Tomm22/Tomm40 overexpressing C2C12 cells. Arrowheads indicate mitophagosomes. (B) Analysis of mitochondrial morphology and damage in EV or 2 µM simvastatin + EV, T22, T40, or T22/40 overexpression in C2C12 cells. Bar graph represents percent of cells exhibiting type 1 mitochondria. (C) Bar graph represents percent of types 2 and 3 mitochondria in EV or 2 µM simvastatin + EV, T22, T40, or T22/40 overexpression in C2C12 cells (n = 10–15 cells). (D) Percent of mitophagosomes per total number of mitochondria per cell, identified from TEM images (n = 10–15 cells). (E,F) mRNA transcript levels of Pink1/PINK1 and Prkn/PRKN (mitophagy) were quantified using qPCR in EV vs. 2 µM simvastatin + EV, TOMM22, TOMM40, TOMM20, or TOMM20/22/40 in (E) C2C12 and (F) hSkMC myotubes (n = 3 biological replicates). All graphical and numeric data represent the mean ± SEM. * p < 0.05, ** p < 0.01, ***p < 0.001, **** p < 0.0001 vs. EV by one-way ANOVA, with Tukey’s post hoc test to identify differences between groups. p < 0.05 for a vs. b vs. c by two-way ANOVA, with Sidak’s multiple comparisons test.
Figure 8. Overexpression of TOMM40 and TOMM22, but not TOMM20, rescues simvastatin-induced mitophagy leading to reduced mitochondrial damage. (A) TEM micrographs of mitophagosomes found in EV, 2 µM simvastatin + EV, and 2 µM simvastatin + Tomm22/Tomm40 overexpressing C2C12 cells. Arrowheads indicate mitophagosomes. (B) Analysis of mitochondrial morphology and damage in EV or 2 µM simvastatin + EV, T22, T40, or T22/40 overexpression in C2C12 cells. Bar graph represents percent of cells exhibiting type 1 mitochondria. (C) Bar graph represents percent of types 2 and 3 mitochondria in EV or 2 µM simvastatin + EV, T22, T40, or T22/40 overexpression in C2C12 cells (n = 10–15 cells). (D) Percent of mitophagosomes per total number of mitochondria per cell, identified from TEM images (n = 10–15 cells). (E,F) mRNA transcript levels of Pink1/PINK1 and Prkn/PRKN (mitophagy) were quantified using qPCR in EV vs. 2 µM simvastatin + EV, TOMM22, TOMM40, TOMM20, or TOMM20/22/40 in (E) C2C12 and (F) hSkMC myotubes (n = 3 biological replicates). All graphical and numeric data represent the mean ± SEM. * p < 0.05, ** p < 0.01, ***p < 0.001, **** p < 0.0001 vs. EV by one-way ANOVA, with Tukey’s post hoc test to identify differences between groups. p < 0.05 for a vs. b vs. c by two-way ANOVA, with Sidak’s multiple comparisons test.
Ijms 26 10977 g008
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Yang, N.V.; Rogers, S.; Guerra, R.; Chao, J.Y.; Pagliarini, D.J.; Theusch, E.; Krauss, R.M. Targeting TOMM40 and TOMM22 to Rescue Statin-Impaired Mitochondrial Function, Dynamics, and Mitophagy in Skeletal Myotubes. Int. J. Mol. Sci. 2025, 26, 10977. https://doi.org/10.3390/ijms262210977

AMA Style

Yang NV, Rogers S, Guerra R, Chao JY, Pagliarini DJ, Theusch E, Krauss RM. Targeting TOMM40 and TOMM22 to Rescue Statin-Impaired Mitochondrial Function, Dynamics, and Mitophagy in Skeletal Myotubes. International Journal of Molecular Sciences. 2025; 26(22):10977. https://doi.org/10.3390/ijms262210977

Chicago/Turabian Style

Yang, Neil V., Sean Rogers, Rachel Guerra, Justin Y. Chao, David J. Pagliarini, Elizabeth Theusch, and Ronald M. Krauss. 2025. "Targeting TOMM40 and TOMM22 to Rescue Statin-Impaired Mitochondrial Function, Dynamics, and Mitophagy in Skeletal Myotubes" International Journal of Molecular Sciences 26, no. 22: 10977. https://doi.org/10.3390/ijms262210977

APA Style

Yang, N. V., Rogers, S., Guerra, R., Chao, J. Y., Pagliarini, D. J., Theusch, E., & Krauss, R. M. (2025). Targeting TOMM40 and TOMM22 to Rescue Statin-Impaired Mitochondrial Function, Dynamics, and Mitophagy in Skeletal Myotubes. International Journal of Molecular Sciences, 26(22), 10977. https://doi.org/10.3390/ijms262210977

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop